Burden of liver diseases in the world

Journal of Hepatology

Volumn 70, Issue 1, 2019, Pages 151-171

  Asrani, Sumeet K ^a   Devarbhavi, Harshad ^b   Eaton, John ^c   Kamath, Patrick S ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

Burden; Chronic liver disease

Indexed keywords

ACUTE HEPATITIS; ACUTE LIVER FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; CANCER RISK; CAUSE OF DEATH; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DIABETES MELLITUS; DISABILITY-ADJUSTED LIFE YEAR; DISEASE BURDEN; HEPATIC ENCEPHALOPATHY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; TOXIC HEPATITIS; VIRUS HEPATITIS; WILSON DISEASE; CHRONIC DISEASE; GLOBAL HEALTH; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

CAUSE OF DEATH; CHRONIC DISEASE; GLOBAL HEALTH; HUMANS; LIVER DISEASES; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 85056129059     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.09.014     Document Type: Review

References (243)

1. Mokdad, A.A., Lopez, A.D., Shahraz, S., Lozano, R., Mokdad, A.H., Stanaway, J., et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med, 12, 2014, 145.
2. Haberman, P.W., Weinbaum, D.F., Liver cirrhosis with and without mention of alcohol as cause of death. Br J Addict 85 (1990), 217–222.
3. Asrani, S.K., Larson, J.J., Yawn, B., Therneau, T.M., Kim, W.R., Underestimation of liver-related mortality in the United States. Gastroenterology 145 (2013), 375–382 e371–372.
4. Mokdad, A.H., Forouzanfar, M.H., Daoud, F., Mokdad, A.A., El Bcheraoui, C., Moradi-Lakeh, M., et al. Global burden of diseases, injuries, and risk factors for young people's health during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 387 (2016), 2383–2401.
5. Beste, L.A., Leipertz, S.L., Green, P.K., Dominitz, J.A., Ross, D., Ioannou, G.N., Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology, 149, 2015 1471-1482.e1475; quiz e1417-1478.
6. Mokdad, A.A., Lopez, A.D., Shahraz, S., Lozano, R., Mokdad, A.H., Stanaway, J., et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 12 (2014), 014–0145.
7. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
8. Dondog, B., Lise, M., Dondov, O., Baldandorj, B., Franceschi, S., Hepatitis B and C virus infections in hepatocellular carcinoma and cirrhosis in Mongolia. Eur J Cancer Prev 20 (2011), 33–39.
9. Stepanova, M., De Avila, L., Afendy, M., Younossi, I., Pham, H., Cable, R., et al. Direct and indirect economic burden of chronic liver disease in the United States. Clin Gastroenterol Hepatol, 2016.
10. WHO, Global health estimates 2015: deaths by cause, age, sex, by country and by region, 2000–2015. 2016, World Health Organization, Geneva.
11. WHO, Global health estimates 2015: disease burden by cause, age, sex, by country and by region, 2000-2015. 2016, World Health Organization, Geneva.
12. Peery, A.F., Crockett, S.D., Barritt, A.S., Dellon, E.S., Eluri, S., Gangarosa, L.M., et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology 149 (2015), 1731–1741.e1733.
13. Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., Patra, J., Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373 (2009), 2223–2233.
14. WHO, Global status report on alcohol 2004. 2004, World Health Organization, Geneva.
15. Rehm, J., Samokhvalov, A.V., Shield, K.D., Global burden of alcoholic liver diseases. J Hepatol 59 (2013), 160–168.
16. WHO. Global status report on alcohol and health 2014. 2014.
17. Stein, E., Cruz-Lemini, M., Altamirano, J., Ndugga, N., Couper, D., Abraldes, J.G., et al. Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. J Hepatol 65 (2016), 998–1005.
18. Younossi, Z.M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol, 9, 2011 524-530.e521; quiz e560.
19. Naveau, S., Giraud, V., Borotto, E., Aubert, A., Capron, F., Chaput, J.C., Excess weight risk factor for alcoholic liver disease. Hepatology 25 (1997), 108–111.
20. Deleuran, T., Gronbaek, H., Vilstrup, H., Jepsen, P., Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study. Aliment Pharmacol Ther 35 (2012), 1336–1342.
21. Raynard, B., Balian, A., Fallik, D., Capron, F., Bedossa, P., Chaput, J.C., et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35 (2002), 635–638.
22. Mathurin, P., Beuzin, F., Louvet, A., Carrie-Ganne, N., Balian, A., Trinchet, J.C., et al. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther 25 (2007), 1047–1054.
23. Haflidadottir, S., Jonasson, J.G., Norland, H., Einarsdottir, S.O., Kleiner, D.E., Lund, S.H., et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol, 14, 2014, 166.
24. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O, EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Jurnal Hepatol 64 (2016), 1388–1402.
25. Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L., Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307 (2012), 491–497.
26. Rinella, M., Charlton, M., The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology 64 (2016), 19–22.
27. Collaboration NCDRF, Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 390 (2017), 2627–2642.
28. Collaboration NCDRF, Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387 (2016), 1513–1530.
29. Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
30. Kanwal, F., Kramer, J.R., Duan, Z., Yu, X., White, D., El-Serag, H.B., Trends in the burden of nonalcoholic fatty liver disease in a united states cohort of veterans. Clin Gastroenterol Hepatol, 14, 2016 301–308.e301-302.
31. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
32. Seki, Y., Kakizaki, S., Horiguchi, N., Hashizume, H., Tojima, H., Yamazaki, Y., et al. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery. J Gastroenterolgy 51 (2016), 281–289.
33. Forlani, G., Giorda, C., Manti, R., Mazzella, N., De Cosmo, S., Rossi, M.C., et al. The burden of NAFLD and Its characteristics in a nationwide population with Type 2 diabetes. J Diab Res, 2016, 2016, 2931985.
34. Diehl, A.M., Day, C., Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377 (2017), 2063–2072.
35. Xu, C., Yu, C., Ma, H., Xu, L., Miao, M., Li, Y., Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol 108 (2013), 1299–1304.
36. Seto, W.K., Yuen, M.F., Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol 52 (2017), 164–174.
37. Sayiner, M., Koenig, A., Henry, L., Younossi, Z.M., Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 20 (2016), 205–214.
38. Lazo, M., Hernaez, R., Eberhardt, M.S., Bonekamp, S., Kamel, I., Guallar, E., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 178 (2013), 38–45.
39. Younossi, Z.M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64 (2016), 1577–1586.
40. Estes, C., Razavi, H., Loomba, R., Younossi, Z., Sanyal, A.J., Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67 (2018), 123–133.
41. Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin gastroenterol Hepatol, 13, 2015 643–654 e641–649; quiz e639–640.
42. Hart, C.L., Morrison, D.S., Batty, G.D., Mitchell, R.J., Davey, Smith G., Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ, 340, 2010.
43. WHO. Global hepatitis report. 2017:1-83.
44. Murray, C.J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A.D., Michaud, C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2197–2223.
45. Stanaway, J.D., Flaxman, A.D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388 (2016), 1081–1088.
46. Franco, E., Meleleo, C., Serino, L., Sorbara, D., Zaratti, L., Hepatitis A: epidemiology and prevention in developing countries. World J Hepatol 4 (2012), 68–73.
47. Jacobsen, K.H., Wiersma, S.T., Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 28 (2010), 6653–6657.
48. Uruena, A., Gonzalez, J.E., Rearte, A., Perez Carrega, M.E., Calli, R., Pagani, M.F., et al. Single-dose universal hepatitis A immunization in one-year-old children in Argentina: high prevalence of protective antibodies up to 9 years after vaccination. Pediatr Infect Dis J 35 (2016), 1339–1342.
49. Vizzotti, C., Gonzalez, J., Gentile, A., Rearte, A., Ramonet, M., Canero-Velasco, M.C., et al. Impact of the single-dose immunization strategy against hepatitis A in Argentina. Pediatr Infect Dis J 33 (2014), 84–88.
50. Cooksley, W.G., What did we learn from the Shanghai hepatitis A epidemic?. J Viral Hepat 7 (2000), 1–3.
51. Lemon, S.M., Ott, J.J., Van Damme, P., Shouval, D., Type A viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol 68 (2018), 167–184.
52. Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G., Ott, J.J., Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
53. Pimpin, L., Cortez-Pinto, H., Negro, F., Corbould, E., Lazarus, J.V., Webber, L., et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol 69 (2018), 718–735.
54. EASL, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67 (2017), 370–398.
55. Ni, Y.H., Chen, D.S., Hepatitis B vaccination in children: the Taiwan experience. Pathol Biol 58 (2010), 296–300.
56. Degenhardt, L., Charlson, F., Stanaway, J., Larney, S., Alexander, L.T., Hickman, M., et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis 16 (2016), 1385–1398.
57. Papatheodoridis, G.V., Sypsa, V., Dalekos, G., Yurdaydin, C., van Boemmel, F., Buti, M., et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol 68 (2018), 1129–1136.
58. Papatheodoridis, G.V., Idilman, R., Dalekos, G.N., Buti, M., Chi, H., van Boemmel, F., et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 66 (2017), 1444–1453.
59. Papatheodoridis, M., Rigopoulou, E., Hadziyannis, E., Kalliopi, Z., Xourafas, V., Lyberopoulou, A., et al. PS-159 - Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in noncirrhotic HBeAg-negative chronic hepatitis B patients: results from the DARING-B prospective Greek study. J Hepatol 68 (2018), S88–S89.
60. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161–176.
61. Hahne, S.J., Veldhuijzen, I.K., Wiessing, L., Lim, T.A., Salminen, M., Laar, M., Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis, 13, 2013, 181.
62. Broome, U., Olsson, R., Loof, L., Bodemar, G., Hultcrantz, R., Danielsson, A., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38 (1996), 610–615.
63. Rehm, J., Shield, K.D., Global alcohol-attributable deaths from cancer, liver cirrhosis, and injury in 2010. Alcohol Res: Curr Rev 35 (2013), 174–183.
64. Falla, A.M., Hofstraat, S.H.I., Duffell, E., Hahne, S.J.M., Tavoschi, L., Veldhuijzen, I.K., Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis, 18, 2018, 79.
65. Wiessing, L., Ferri, M., Grady, B., Kantzanou, M., Sperle, I., Cullen, K.J., et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS ONE, 9, 2014.
66. www.who.int/mediacentre/factsheets/fs164/en.
67. Kanwal, F., Hoang, T., Kramer, J.R., Asch, S.M., Goetz, M.B., Zeringue, A., et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology, 140, 2011 1182–1188 e1181.
68. Razavi, H., Waked, I., Sarrazin, C., Myers, R.P., Idilman, R., Calinas, F., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 1 (2014), 34–59.
69. Hughes, S.A., Wedemeyer, H., Harrison, P.M., Hepatitis delta virus. Lancet 378 (2011), 73–85.
70. Pascarella, S., Negro, F., Hepatitis D virus: an update. Liver Int 31 (2011), 7–21.
71. Chen, X., Oidovsambuu, O., Liu, P., Grosely, R., Elazar, M., Winn, V.D., et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. Hepatology 66 (2017), 1739–1749.
72. Rizzetto, M., Chronic Hepatitis D; at a standstill?. Dig Dis (Basel, Switzerland) 34 (2016), 303–307.
73. Wedemeyer, H., Heidrich, B., Manns, M.P., Hepatitis D virus infection–not a vanishing disease in Europe!. Hepatology, 45, 2007, 10.1002/hep.21590.
74. Rein, D.B., Stevens, G.A., Theaker, J., Wittenborn, J.S., Wiersma, S.T., The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 55 (2012), 988–997.
75. European Association for the Study of the Liver, EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol 68 (2018), 1256–1271.
76. Woo, P.C., Lau, S.K., Teng, J.L., Cao, K.Y., Wernery, U., Schountz, T., et al. New Hepatitis E virus genotype in bactrian camels, Xinjiang, China, 2013. Emerg Infect Dis 22 (2016), 2219–2221.
77. Lee, G.H., Tan, B.H., Teo, E.C., Lim, S.G., Dan, Y.Y., Wee, A., et al. Chronic infection with camelid Hepatitis E virus in a liver transplant recipient who regularly consumes camel meat and milk. Gastroenterology, 150, 2016 355–357 e353.
78. Bhatia, V., Singhal, A., Panda, S.K., Acharya, S.K., A 20-year single-center experience with acute liver failure during pregnancy: is the prognosis really worse?. Hepatology 48 (2008), 1577–1585.
79. Kamar, N., Bendall, R., Legrand-Abravanel, F., Xia, N.S., Ijaz, S., Izopet, J., et al. Hepatitis E. Lancet 379 (2012), 2477–2488.
80. Debing, Y., Moradpour, D., Neyts, J., Gouttenoire, J., Update on hepatitis E virology: implications for clinical practice. J Hepatol 65 (2016), 200–212.
81. Blasco-Perrin, H., Madden, R.G., Stanley, A., Crossan, C., Hunter, J.G., Vine, L., et al. Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study. Aliment Pharmacol Ther 42 (2015), 574–581.
82. Boonstra, K., Beuers, U., Ponsioen, C.Y., Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 56 (2012), 1181–1188.
83. Boonstra, K., Weersma, R.K., van Erpecum, K.J., Rauws, E.A., Spanier, B.W., Poen, A.C., et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58 (2013), 2045–2055.
84. Eaton, J.E., Talwalkar, J.A., Lazaridis, K.N., Gores, G.J., Lindor, K.D., Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 145 (2013), 521–536.
85. Karlsen, T.H., Folseraas, T., Thorburn, D., Vesterhus, M., Primary sclerosing cholangitis – a comprehensive review. J Hepatol 67 (2017), 1298–1323.
86. Kuo, A., Gomel, R., Safer, R., Lindor, K.D., Everson, G.T., Bowlus, C.L., Characteristics and outcomes reported by patients with primary sclerosing cholangitis through an online registry. Clin Gastroenterol Hepatol, 2018.
87. Deneau, M.R., El-Matary, W., Valentino, P.L., Abdou, R., Alqoaer, K., Amin, M., et al. The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration. Hepatology 66 (2017), 518–527.
88. Lunder, A.K., Hov, J.R., Borthne, A., Gleditsch, J., Johannesen, G., Tveit, K., et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology 151 (2016), 660–669.
89. Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Loof, L., Danielsson, A., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36 (2002), 321–327.
90. Valle, J.W., Borbath, I., Khan, S.A., Huguet, F., Gruenberger, T., Arnold, D., et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27 (2016), v28–v37.
91. Bergquist, A., von Seth, E., Epidemiology of cholangiocarcinoma. Best Prac Res Clin Gastroenterol 29 (2015), 221–232.
92. Palmer, W.C., Patel, T., Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 57:1 (2012), 69–76.
93. Ren, H.B., Yu, T., Liu, C., Li, Y.Q., Diabetes mellitus and increased risk of biliary tract cancer: systematic review and meta-analysis. Cancer Causes Control 22 (2011), 837–847.
94. Li, H., Hu, B., Zhou, Z.Q., Guan, J., Zhang, Z.Y., Zhou, G.W., Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies. World J Surg Oncol, 13, 2015, 161.
95. Zhou, Y., Zhao, Y., Li, B., Huang, J., Wu, L., Xu, D., et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer, 12, 2012, 289.
96. Shin, H.R., Oh, J.K., Masuyer, E., Curado, M.P., Bouvard, V., Fang, Y.Y., et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 101 (2010), 579–585.
97. Burak, K., Angulo, P., Pasha, T.M., Egan, K., Petz, J., Lindor, K.D., Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 99 (2004), 523–526.
98. Rizvi, S., Eaton, J.E., Gores, G.J., Primary sclerosing cholangitis as a premalignant biliary tract disease: surveillance and management. Clin Gastroenterol Hepatol 13 (2015), 2152–2165.
99. Sripa, B., Pairojkul, C., Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol 24 (2008), 349–356.
100. Tyson, G.L., El-Serag, H.B., Risk factors for cholangiocarcinoma. Hepatology 54 (2011), 173–184.
101. Khan, S.A., Emadossadaty, S., Ladep, N.G., Thomas, H.C., Elliott, P., Taylor-Robinson, S.D., et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J Hepatol 56 (2012), 848–854.
102. Welzel, T.M., McGlynn, K.A., Hsing, A.W., O'Brien, T.R., Pfeiffer, R.M., Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 98 (2006), 873–875.
103. Khan, S.A., Emadossadaty, S., Ladep, N.G., Thomas, H.C., Elliott, P., Taylor-Robinson, S.D., et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J Hepatol 56 (2012), 848–854.
104. Ebata, T., Ercolani, G., Alvaro, D., Ribero, D., Di Tommaso, L., Valle, J.W., Current status on cholangiocarcinoma and gallbladder cancer. Liver Cancer 6 (2016), 59–65.
105. Khan, S.A., Taylor-Robinson, S.D., Toledano, M.B., Beck, A., Elliott, P., Thomas, H.C., Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37 (2002), 806–813.
106. Patel, T., Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33 (2001), 1353–1357.
107. Yang, J.D., Kim, B., Sanderson, S.O., Sauver, J.S., Yawn, B.P., Larson, J.J., et al. Biliary tract cancers in Olmsted County, Minnesota, 1976–2008. Am J Gastroenterol 107 (2012), 1256–1262.
108. Petrick, J.L., Braunlin, M., Laversanne, M., Valery, P.C., Bray, F., McGlynn, K.A., International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer 139 (2016), 1534–1545.
109. Saha, S.K., Zhu, A.X., Fuchs, C.S., Brooks, G.A., Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 21:5 (2016), 594–599.
110. Shaib, Y., El-Serag, H.B., The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:2 (2004), 115–125.
111. Petrick, J.L., Braunlin, M., Laversanne, M., Valery, P.C., Bray, F., McGlynn, K.A., International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer 139 (2016), 1534–1545.
112. Baldursdottir, T.R., Bergmann, O.M., Jonasson, J.G., Ludviksson, B.R., Axelsson, T.A., Bjornsson, E.S., The epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study. Eur J Gastroenterol Hepatol 24 (2012), 824–830.
113. Kim, W.R., Lindor, K.D., Locke, G.R. 3rd, Therneau, T.M., Homburger, H.A., Batts, K.P., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 119 (2000), 1631–1636.
114. European Association for the Study of the Liver, EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67 (2017), 145–172.
115. Mells, G.F., Pells, G., Newton, J.L., Bathgate, A.J., Burroughs, A.K., Heneghan, M.A., et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 58 (2013), 273–283.
116. Prince, M., Chetwynd, A., Newman, W., Metcalf, J.V., James, O.F., Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123 (2002), 1044–1051.
117. Boonstra, K., Kunst, A.E., Stadhouders, P.H., Tuynman, H.A., Poen, A.C., van Nieuwkerk, K.M., et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int, 34, 2014, 14.
118. Dahlqvist, G., Gaouar, F., Carrat, F., Meurisse, S., Chazouilleres, O., Poupon, R., et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology 65 (2017), 152–163.
119. Lammers, W.J., van Buuren, H.R., Hirschfield, G.M., Janssen, H.L., Invernizzi, P., Mason, A.L., et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 147 (2014), 1338–1349.
120. Carbone, M., Bufton, S., Monaco, A., Griffiths, L., Jones, D.E., Neuberger, J.M., The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol 59 (2013), 490–494.
121. Liberal, R., Krawitt, E.L., Vierling, J.M., Manns, M.P., Mieli-Vergani, G., Vergani, D., Cutting edge issues in autoimmune hepatitis. J Autoimmun 75 (2016), 6–19.
122. Danielsson Borssen, A., Marschall, H.U., Bergquist, A., Rorsman, F., Weiland, O., Kechagias, S., et al. Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. Scandinavian J Gastroenterol 52 (2017), 1022–1028.
123. van Gerven, N.M., Verwer, B.J., Witte, B.I., van Erpecum, K.J., van Buuren, H.R., Maijers, I., et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 49 (2014), 1245–1254.
124. Gronbaek, L., Vilstrup, H., Jepsen, P., Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 60 (2014), 612–617.
125. Tanaka, A., Ma, X., Yokosuka, O., Weltman, M., You, H., Amarapurkar, D.N., et al. Autoimmune liver diseases in the Asia-Pacific region: proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int 10 (2016), 909–915.
126. Mieli-Vergani, G., Vergani, D., Czaja, A.J., Manns, M.P., Krawitt, E.L., Vierling, J.M., et al. Autoimmune hepatitis. Nat Rev Dis Primers, 4, 2018, 18017.
127. de Boer, Y.S., van Gerven, N.M., Zwiers, A., Verwer, B.J., van Hoek, B., van Erpecum, K.J., et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology, 147, 2014 443-452 e445.
128. Aggarwal, A., Chandhok, G., Todorov, T., Parekh, S., Tilve, S., Zibert, A., et al. Wilson disease mutation pattern with genotype-phenotype correlations from Western India: confirmation of p.C271* as a common Indian mutation and identification of 14 novel mutations. Ann Human Genetics 77 (2013), 299–307.
129. European Association for Study of L, EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 56 (2012), 671–685.
130. Coffey, A.J., Durkie, M., Hague, S., McLay, K., Emmerson, J., Lo, C., et al. A genetic study of Wilson's disease in the United Kingdom. Brain 136 (2013), 1476–1487.
131. Onakpoya, I.J., Heneghan, C.J., Aronson, J.K., Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med 14 (2016), 016–0553.
132. Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., Guilleminet, C., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36 (2002), 451–455.
133. Bjornsson, E.S., Bergmann, O.M., Bjornsson, H.K., Kvaran, R.B., Olafsson, S., Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144 (2013), 1419–1425.
134. Hussaini, S.H., O'Brien, C.S., Despott, E.J., Dalton, H.R., Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol 19 (2007), 15–20.
135. de Abajo, F.J., Montero, D., Madurga, M., Garcia Rodriguez, L.A., Acute and clinically relevant drug-induced liver injury: a population-based case-control study. Br J Clin Pharmacol 58 (2004), 71–80.
136. Meier, Y., Cavallaro, M., Roos, M., Pauli-Magnus, C., Folkers, G., Meier, P.J., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 61 (2005), 135–143.
137. De Valle, M.B., Av Klinteberg, V., Alem, N., Olsson, R., Bjornsson, E., Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Alimentary Pharmacol Ther 24:8 (2006), 1187–1195.
138. Devarbhavi, H., Dierkhising, R., Kremers, W.K., Sandeep, M.S., Karanth, D., Adarsh, C.K., Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 105 (2010), 2396–2404.
139. Bjornsson, E.S., Hoofnagle, J.H., Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology 63 (2016), 590–603.
140. Devarbhavi, H., Andrade, R.J., Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. Semin Liver Dis 34 (2014), 145–161.
141. Garcia Rodriguez, L.A., Ruigomez, A., Jick, H., A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy 17 (1997), 721–728.
142. Chalasani, N., Bonkovsky, H.L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148 (2015), 1340–1352.
143. Suk, K.T., Kim, D.J., Kim, C.H., Park, S.H., Yoon, J.H., Kim, Y.S., et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 107 (2012), 1380–1387.
144. WHO. Global Tuberculosis Report. 2017.
145. Zhou, Y., Yang, L., Liao, Z., He, X., Zhou, Y., Guo, H., Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol 25 (2013), 825–829.
146. Navarro, V.J., Barnhart, H., Bonkovsky, H.L., Davern, T., Fontana, R.J., Grant, L., et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 60 (2014), 1399–1408.
147. Seeff, L.B., Bonkovsky, H.L., Navarro, V.J., Wang, G., Herbal products and the liver: a review of adverse effects and mechanisms. Gastroenterology 148 (2015), 517–532.
148. Escorsell, A., Mas, A., de la Mata, M., Acute liver failure in Spain: analysis of 267 cases. Liver Transpl 13 (2007), 1389–1395.
149. Bower, W.A., Johns, M., Margolis, H.S., Williams, I.T., Bell, B.P., Population-based surveillance for acute liver failure. Am J Gastroenterol 102 (2007), 2459–2463.
150. Bernal, W., Wendon, J., Acute liver failure. N Engl J Med 369:26 (2013), 2525–2534.
151. Reuben, A., Tillman, H., Fontana, R.J., Davern, T., McGuire, B., Stravitz, R.T., et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann Internal Med 164:11 (2016), 724–732.
152. Bernal, W., Hyyrylainen, A., Gera, A., Audimoolam, V.K., McPhail, M.J., Auzinger, G., et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 59 (2013), 74–80.
153. Devarbhavi, H., Patil, M., Reddy, V.V., Singh, R., Joseph, T., Ganga, D., Drug-induced acute liver failure in children and adults: results of a single-centre study of 128 patients. Liver Int, 9, 2017, 13662.
154. Devarbhavi, H., Acute liver failure induced by anti-infectious drugs: causes and management. Curr Hepatol Rep 16:4 (2017), 276–285.
155. Tujios, S.R., Lee, W.M., Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. Liver Int 38 (2018), 6–14.
156. Zhao, P., Wang, C., Liu, W., Chen, G., Liu, X., Wang, X., et al. Causes and outcomes of acute liver failure in China. PLoS ONE, 8, 2013.
157. Squires, R.H. Jr., Shneider, B.L., Bucuvalas, J., Alonso, E., Sokol, R.J., Narkewicz, M.R., et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatrics 148 (2006), 652–658.
158. Shalimar, Kedia S., Gunjan, D., Sonika, U., Mahapatra, S.J., Nayak, B., et al. Acute liver failure due to Hepatitis E virus infection is associated with better survival than other etiologies in Indian patients. Digest Dis Sci 62 (2017), 1058–1066.
159. Fleming, K.M., Aithal, G.P., Card, T.R., West, J., All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int 32 (2012), 79–84.
160. D'Amico, G., Garcia-Tsao, G., Pagliaro, L., Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44 (2006), 217–231.
161. D'Amico, G., Morabito, A., D'Amico, M., Pasta, L., Malizia, G., Rebora, P., et al. Clinical states of cirrhosis and competing risks. J Hepatol 68 (2018), 563–576.
162. Ratib, S., Fleming, K.M., Crooks, C.J., Walker, A.J., West, J., Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study. Am J Gastroenterol 110 (2015), 1149–1158.
163. D'Amico, G., Pasta, L., Morabito, A., D'Amico, M., Caltagirone, M., Malizia, G., et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Alimentary Pharmacol Ther 39 (2014), 1180–1193.
164. Fleming, K.M., Aithal, G.P., Card, T.R., West, J., The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Alimentary Pharmacol Ther 32 (2010), 1343–1350.
165. Schuppan, D., Afdhal, N.H., Liver cirrhosis. Lancet 371 (2008), 838–851.
166. Groszmann, R.J., Garcia-Tsao, G., Bosch, J., Grace, N.D., Burroughs, A.K., Planas, R., et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353 (2005), 2254–2261.
167. Merli, M., Nicolini, G., Angeloni, S., Rinaldi, V., De Santis, A., Merkel, C., et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 38 (2003), 266–272.
168. Planas, R., Montoliu, S., Balleste, B., Rivera, M., Miquel, M., Masnou, H., et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 4 (2006), 1385–1394.
169. Jepsen, P., Ott, P., Andersen, P.K., Sorensen, H.T., Vilstrup, H., Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 51 (2010), 1675–1682.
170. Arvaniti, V., D'Amico, G., Fede, G., Manousou, P., Tsochatzis, E., Pleguezuelo, M., et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology, 139, 2010 1246-1256, 1256 e1241-1245.
171. Fede, G., D'Amico, G., Arvaniti, V., Tsochatzis, E., Germani, G., Georgiadis, D., et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 56 (2012), 810–818.
172. Mukherjee, P.S., Vishnubhatla, S., Amarapurkar, D.N., Das, K., Sood, A., Chawla, Y.K., et al. Etiology and mode of presentation of chronic liver diseases in India: a multi centric study. PLoS ONE, 12, 2017.
173. Haj, M., Hart, M., Rockey, D.C., Development of a novel clinical staging model for cirrhosis using the Nationwide Inpatient Sample. J Investig Med, 2018.
174. Asrani, S.K., Hall, L., Hagan, M., Sharma, S., Yeramaneni, S., Trotter, J., Talwalkar, J., Kanwal, F., Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. Am J Gastroenterol, 64, 2018, 10.1038/s41395-018-0365-4 [Epub ahead of print] PMID: 30333543.
175. Allen, A.M., Kim, W.R., Epidemiology and healthcare burden of acute-on-chronic liver failure. Seminars Liver Dis 36 (2016), 123–126.
176. Qin, G., Shao, J.G., Zhu, Y.C., Xu, A.D., Yao, J.H., Wang, X.L., et al. Population-representative incidence of acute-on-chronic liver failure: a prospective cross-sectional study. J Clin Gastroenterol 50 (2016), 670–675, 10.1097/MCG.0000000000000538 Epub 2016 Aug 10.
177. Kim, H.Y., Kim, C.W., Kim, T.Y., Song, D.S., Sinn, D.H., Yoon, E.L., et al. Assessment of scoring systems for acute-on-chronic liver failure at predicting short-term mortality in patients with alcoholic hepatitis. World J Gastroenterol: WJG 22 (2016), 9205–9213.
178. Moreau, R., Jalan, R., Gines, P., Pavesi, M., Angeli, P., Cordoba, J., et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology, 144, 2013 1426-1437, 1437 e1421-1429.
179. Bajaj, J.S., O'Leary, J.G., Reddy, K.R., Wong, F., Biggins, S.W., Patton, H., et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 60 (2014), 250–256.
180. Sargenti, K., Prytz, H., Nilsson, E., Kalaitzakis, E., Predictors of mortality among patients with compensated and decompensated liver cirrhosis: the role of bacterial infections and infection-related acute-on-chronic liver failure. Scand J Gastroenterol 50 (2015), 875–883.
181. Shi, Y., Yang, Y., Hu, Y., Wu, W., Yang, Q., Zheng, M., et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 62 (2015), 232–242.
182. Li, H., Chen, L.Y., Zhang, N.N., Li, S.T., Zeng, B., Pavesi, M., et al. Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to Hepatitis B. Sci Rep, 6, 2016.
183. Moreau, R., Jalan, R., Gines, P., Pavesi, M., Angeli, P., Cordoba, J., et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144 (2013), 1426–1437.
184. Kim, T.Y., Song, D.S., Kim, H.Y., Sinn, D.H., Yoon, E.L., Kim, C.W., et al. Characteristics and discrepancies in acute-on-chronic liver failure: need for a unified definition. PLoS ONE, 11, 2016.
185. Allen, A.M., Kim, W.R., Moriarty, J.P., Shah, N.D., Larson, J.J., Kamath, P.S., Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology 64 (2016), 2165–2172.
186. Zhang, Q., Li, Y., Han, T., Nie, C., Cai, J., Liu, H., et al. Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS ONE, 10, 2015.
187. S. Piano V. Singh P. Caraceni R. Maiwall C. Alessandria J. Fernandez et al. Epidemiology, predictors and outcomes of multi drug resistant bacterial infections in patients with cirrhosis across the world. Final results of the “Global study” J Hepatol 2018 68 S1.
188. Fitzmaurice, C., Allen, C., Barber, R.M., Barregard, L., Bhutta, Z.A., Brenner, H., et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol, 2016.
189. Brown, R.S. Jr., Lake, J.R., The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant 5 (2005), 203–204.
190. 1973-2015 SRD. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2015). National Cancer Institute, DCCPS, Surveillance Research Program released April 2018, based on the November 2017 submission.
191. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013; http://globocan.iarc.fr. Accessed 1/2/2017, 2017.
192. McGlynn, K.A., Petrick, J.L., London, W.T., Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 19 (2015), 223–238.
193. El-Serag, H.B., Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142, 2012 1264–1273 e1261.
194. Wong, R., Corley, D.A., Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med 121 (2008), 525–531.
195. Wong, R.J., Cheung, R., Ahmed, A., Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59 (2014), 2188–2195.
196. de Martel, C., Maucort-Boulch, D., Plummer, M., Franceschi, S., World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 62 (2015), 1190–1200.
197. Yang, J.D., Altekruse, S.F., Nguyen, M.H., Gores, G.J., Roberts, L.R., Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. Cancer 123 (2017), 81–89.
198. Yang, H.I., Yeh, S.H., Chen, P.J., Iloeje, U.H., Jen, C.L., Su, J., et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100 (2008), 1134–1143.
199. Kao, J.H., Chen, P.J., Lai, M.Y., Chen, D.S., Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124 (2003), 327–334.
200. Chen, C.J., Yang, H.I., Su, J., Jen, C.L., You, S.L., Lu, S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006), 65–73.
201. Raimondi, S., Bruno, S., Mondelli, M.U., Maisonneuve, P., Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 50 (2009), 1142–1154.
202. Wallace, M.C., Preen, D., Jeffrey, G.P., Adams, L.A., The evolving epidemiology of hepatocellular carcinoma: a global perspective. Exp Rev Gastroenterol Hepatol 9 (2015), 765–779.
203. Williams, J.H., Phillips, T.D., Jolly, P.E., Stiles, J.K., Jolly, C.M., Aggarwal, D., Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 80 (2004), 1106–1122.
204. Garner, R.C., Miller, E.C., Miller, J.A., Liver microsomal metabolism of aflatoxin B 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res 32 (1972), 2058–2066.
205. Qian, G.S., Ross, R.K., Yu, M.C., Yuan, J.M., Gao, Y.T., Henderson, B.E., et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prevent 3 (1994), 3–10.
206. Liu, Y., Wu, F., Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 118 (2010), 818–824.
207. Poon, S.L., Pang, S.T., McPherson, J.R., Yu, W., Huang, K.K., Guan, P., et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med, 5, 2013 197ra101.
208. Tsai, J.F., Chuang, L.Y., Jeng, J.E., Ho, M.S., Hsieh, M.Y., Lin, Z.Y., et al. Betel quid chewing as a risk factor for hepatocellular carcinoma: a case-control study. Br J Cancer 84 (2001), 709–713.
209. Tsai, J.F., Jeng, J.E., Chuang, L.Y., Ho, M.S., Ko, Y.C., Lin, Z.Y., et al. Habitual betel quid chewing and risk for hepatocellular carcinoma complicating cirrhosis. Medicine 83 (2004), 176–187.
210. Morgan, T.R., Mandayam, S., Jamal, M.M., Alcohol and hepatocellular carcinoma. Gastroenterology 127 (2004), S87–96.
211. Hutchinson, S.J., Bird, S.M., Goldberg, D.J., Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 3 (2005), 1150–1159.
212. Jee, S.H., Ohrr, H., Sull, J.W., Samet, J.M., Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst 96 (2004), 1851–1856.
213. Lin, C.W., Lin, C.C., Mo, L.R., Chang, C.Y., Perng, D.S., Hsu, C.C., et al. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J Hepatol 58 (2013), 730–735.
214. El-Serag, H.B., Kanwal, F., Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. Hepatology 60 (2014), 1767–1775.
215. Welzel, T.M., Graubard, B.I., Quraishi, S., Zeuzem, S., Davila, J.A., El-Serag, H.B., et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 108 (2013), 1314–1321.
216. Trichopoulos, D., Bamia, C., Lagiou, P., Fedirko, V., Trepo, E., Jenab, M., et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 103 (2011), 1686–1695.
217. Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60 (2014), 110–117.
218. Pearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M.J., Ezzati, M., Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diab Endocrinol 6 (2018), 95–104.
219. Ryerson, A.B., Eheman, C.R., Altekruse, S.F., Ward, J.W., Jemal, A., Sherman, R.L., et al. Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer 122 (2016), 1312–1337.
220. Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. Incidence/mortality data. 2018.
221. Groopman, J.D., Kensler, T.W., Wild, C.P., Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. Annu Rev Public Health 29 (2008), 187–203.
222. Nelson, N.P., Easterbrook, P.J., McMahon, B.J., Epidemiology of Hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis 20 (2016), 607–628.
223. Chien, Y.C., Jan, C.F., Chiang, C.J., Kuo, H.S., You, S.L., Chen, C.J., Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees. Hepatology 60 (2014), 125–132.
224. Wong, G.L., Chan, H.L., Mak, C.W., Lee, S.K., Ip, Z.M., Lam, A.T., et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 58 (2013), 1537–1547.
225. Gordon, S.C., Lamerato, L.E., Rupp, L.B., Li, J., Holmberg, S.D., Moorman, A.C., et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 12 (2014), 885–893.
226. Wirth, T.C., Manns, M.P., The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol 27 (2016), 1467–1474.
227. www.transplant-observatory.org. Global Observatory on Donation and Transplantation. 2015.
228. www.transplant-observatory.org/organ-donation-transplantation-activities-2015-report-2.
229. Kim, W.R., Lake, J.R., Smith, J.M., Skeans, M.A., Schladt, D.P., Edwards, E.B., et al. OPTN/SRTR 2015 annual data report: liver. Am J Transplant 1 (2017), 174–251.
230. www.edqm.eu/en/organ-transplantation-reports-73.html.
231. Trotter, J.F., Cardenas, A., Liver transplantation around the world. Liver Transpl 22 (2016), 1059–1061, 10.1002/lt.24508.
232. Soyama, A., Eguchi, S., Egawa, H., Liver transplantation in Japan. Liver Transpl 22 (2016), 1401–1407.
233. Tacke, F., Kroy, D.C., Barreiros, A.P., Neumann, U.P., Liver transplantation in Germany. Liver Transpl 22 (2016), 1136–1142.
234. Neuberger, J., Liver transplantation in the United Kingdom. Liver Transpl 22 (2016), 1129–1135.
235. Narasimhan, G., Kota, V., Rela, M., Liver transplantation in India. Liver Transpl 22 (2016), 1019–1024.
236. Iqbal, M., Elrayah, E.A., Traynor, O., McCormick, P.A., Liver transplantation in Ireland. Liver Transpl 22 (2016), 1014–1018.
237. McCaughan, G.W., Munn, S.R., Liver transplantation in Australia and New Zealand. Liver Transpl 22 (2016), 830–838.
238. Bittencourt, P.L., Farias, A.Q., Couto, C.A., Liver transplantation in Brazil. Liver Transpl 22 (2016), 1254–1258.
239. de la Rosa, G., Fondevila, C., Navasa, M., Liver transplantation in Spain. Liver Transpl 22 (2016), 1259–1264.
240. Chen, C.L., Kabiling, C.S., Concejero, A.M., Why does living donor liver transplantation flourish in Asia?. Nat Rev Gastroenterol Hepatol 10 (2013), 746–751, 10.1038/nrgastro.2013.194 Epub 2013 Oct 8.
241. Lee, S.G., Moon, D.B., Hwang, S., Ahn, C.S., Kim, K.H., Song, G.W., et al. Liver transplantation in Korea: past, present, and future. Transplant Proc 47 (2015), 705–708.
242. Shepherd, L., O'Carroll, R.E., Ferguson, E., An international comparison of deceased and living organ donation/transplant rates in opt-in and opt-out systems: a panel study. BMC Med, 12, 2014 014-0131.
243. Matesanz, R., Dominguez-Gil, B., Coll, E., Mahillo, B., Marazuela, R., How Spain reached 40 deceased organ donors per million population. Am J Transplant 17 (2017), 1447–1454.